Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

How will the in-licensing of a Phase 3-ready oral antibiotic affect BAS's revenue and earnings forecasts? How does this acquisition affect BAS's pipeline timeline and R&D spending? What are the terms of the in-licensing agreement (upfront payment, milestones, royalties) and how will they impact cash flow? What regulatory risks are associated with bringing this drug to market (e.g., FDA/EMA approval timelines)? How does the efficacy and safety profile of the new antibiotic compare to competitors’ products in the same therapeutic area? Will the in-licensed asset create any dilution risk or require additional financing? What are the projected peak sales and market share assumptions for this product? What is the size and growth potential of the market for this novel antibiotic compared to existing treatments? How might this deal influence BAS's strategic positioning and partnership opportunities with larger pharma firms? What potential impact could this news have on short‑term trading volume and volatility of BAS stock?